LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (AMEX: BPA) announced today that it and a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), have signed an amendment to their development and license agreement under which Teva and BioSante will reinitiate their collaboration on the development of a male testosterone therapy product for the U.S. market. Effective immediately, Teva has withdrawn its previous notice of its desire to terminate the license agreement and will reinitiate funding and development of the product.
